This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System
by Zacks Equity Research
BDX wins FDA 510(k) clearance for the EnCor EnCompass breast biopsy system, set for an early 2026 launch to boost flexibility and patient care.
BDXPositive Net Change CAHNegative Net Change COOPositive Net Change VCYTPositive Net Change
medical medical-devices
CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February
by Zacks Equity Research
CAPR said the FDA wants the full HOPE-3 study report for Deramiocel and confirmed no new clinical trials are needed.
BSXPositive Net Change IDXXPositive Net Change STEPositive Net Change CAPRNegative Net Change
medical medical-devices
3 Medical Info Systems Stocks to Gain From Digitization Despite Industry Woes
by Urmimala Biswas
Medical Info Systems rides AI and telehealth tailwinds, lifting DOCS, TXG and OMCL, but cyber risks and industry underperformance keep optimism in check.
DOCSNegative Net Change OMCLPositive Net Change TXGPositive Net Change
artificial-intelligence earnings hospitals medical medical-devices
ISRG vs. MDT: Which MedTech Stock Is a Better Bet Now?
by Indrajit Bandyopadhyay
Intuitive Surgical's pure-play robotics focus, rising da Vinci 5 utilization and 85% recurring revenues tilt the risk-reward versus diversified Medtronic.
MDTPositive Net Change ISRGNegative Net Change
medical medical-devices
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
by Zacks Equity Research
Revvity's diagnostics strength and fast-growing Signals Software support long-term growth, even as macro pressures and weak funding linger.
BSXPositive Net Change IDXXPositive Net Change STEPositive Net Change RVTYPositive Net Change
medical medical-devices
Is IDEXX Laboratories Stock the Right Pick for Your Portfolio Now?
by Zacks Equity Research
IDXX rides on strong CAG Diagnostics momentum and growing global software adoption, but currency pressure and solvency risks cloud the outlook.
BSXPositive Net Change IDXXPositive Net Change PAHCPositive Net Change NVSTPositive Net Change
medical medical-devices
Will GYN Surgical Power Hologic's Growth in the Upcoming Q1 Earnings?
by Moumi Mondal
HOLX's GYN Surgical unit, boosted by MyoSure, Fluent and Gynesonics, drives 10.2% revenue growth and is likely to lift upcoming Q1 results.
ABTPositive Net Change ISRGNegative Net Change HOLXNegative Net Change
medical medical-devices
Intuitive Surgical Pre-Q4 Analysis: Buy, Hold or Sell ISRG Stock Now?
by Zacks Equity Research
ISRG heads into Q4 earnings with 18% procedure growth and da Vinci 5 demand, but valuation and tariffs keep the earnings outlook uncertain.
BSXPositive Net Change ISRGNegative Net Change TMOPositive Net Change
medical medical-devices
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years
by Zacks Equity Research
OGN wins FDA approval to extend NEXPLANON use to five years, backed by trials showing no pregnancies and strong efficacy across body weights.
CRLPositive Net Change MDPositive Net Change ATRCPositive Net Change OGNNegative Net Change
medical medical-devices
Here's Why You Should Retain CLOV Stock in Your Portfolio for Now
by Zacks Equity Research
Clover Health shows strong membership growth, rising revenues and sustained EBITDA gains from Clover Assistant, though near-term margin pressure remains a risk.
CRLPositive Net Change MDPositive Net Change ATRCPositive Net Change CLOVNegative Net Change
medical medical-devices
New Strong Sell Stocks for January 20th
by Zacks Equity Research
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
DARPositive Net Change CADLPositive Net Change DRTSNegative Net Change
consumer-staples medical medical-devices
Should You Still Hold GMED Stock in Your Portfolio?
by Zacks Equity Research
Globus Medical is growing musculoskeletal market share with new product launches, strong finances and international expansion plans.
BSXPositive Net Change GMEDPositive Net Change PAHCPositive Net Change NVSTPositive Net Change
medical medical-devices
How Tilray Brands Is Acting on Its Vast International Opportunity
by Moumi Mondal
TLRY posts a standout international quarter as cannabis revenues jump 36% year over year, driving supply shifts and broader global expansion.
TLRYNegative Net Change VFFNegative Net Change SNDLNo Net Change
medical medical-devices
Elekta Wins FDA Nod for Evo CT-Linac, Boosting U.S. Radiation Oncology
by Zacks Equity Research
EKTAY jumps after FDA clears Evo CT-Linac, opening U.S. access to AI-driven CT imaging that boosts precision and efficiency in radiation therapy.
ISRGNegative Net Change ATRCPositive Net Change EKTAYPositive Net Change VCYTPositive Net Change
medical medical-devices
SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal
by Zacks Equity Research
SNN expands its Sports Medicine portfolio with Integrity Orthopaedics, adding next-gen Tendon Seam tech to strengthen leadership in shoulder repair.
BSXPositive Net Change SNNPositive Net Change IDXXPositive Net Change STEPositive Net Change
medical medical-devices
Here's Why You Should Hold DaVita Stock in Your Portfolio for Now
by Zacks Equity Research
DVA stock benefits from a patient-centric model, third-quarter revenue growth and overseas expansion, though reliance on commercial payers remains a risk.
BSXPositive Net Change DVAPositive Net Change IDXXPositive Net Change STEPositive Net Change
medical medical-devices
Hims & Hers Expands Platform-Led Access to Digital Healthcare
by Debanjana Dey
HIMS leverages a software-driven platform to scale personalized digital care across new health categories and markets.
TDOCPositive Net Change AMWLNo Net Change HIMSNegative Net Change
medical medical-devices
AI, Digital Tools and Hub Data: Could ISRG Evolve Beyond Robotics?
by Indrajit Bandyopadhyay
Intuitive Surgical is positioning da Vinci 5 as a data-driven platform, using AI, software and surgical data to expand beyond robotics into insights.
BSXPositive Net Change ISRGNegative Net Change GEHCPositive Net Change
medical medical-devices
HOLX vs. SYK: Which Medical Device Leader Is a Solid Bet Now?
by Moumi Mondal
Hologic and Stryker gear up for earnings with diagnostic wins, surgical growth and strategic moves shaping the medical device race.
SYKPositive Net Change HOLXNegative Net Change
medical medical-devices
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
by Indrajit Bandyopadhyay
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
IARTPositive Net Change FMSPositive Net Change STEPositive Net Change
medical medical-devices
Top Analyst Reports for Visa, AMD & Thermo Fisher
by Mark Vickery
Visa's volume-driven growth, cross-border expansion and AI investments support long-term prospects, but rising costs and regulatory risks keep the outlook cautious.
AMDPositive Net Change VNegative Net Change MCOPositive Net Change TMOPositive Net Change CAHNegative Net Change PSXPositive Net Change
business-services computers medical-devices
Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
by Zacks Equity Research
ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.
BSXPositive Net Change ISRGNegative Net Change CAHNegative Net Change ATRCPositive Net Change
medical medical-devices
DexCom Stock Declines Following Strong Preliminary Q4 Results
by Zacks Equity Research
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.
BSXPositive Net Change CAHNegative Net Change DXCMPositive Net Change ATRCPositive Net Change
medical medical-devices
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold stance.
OMCLPositive Net Change DXCMPositive Net Change ATRCPositive Net Change PAHCPositive Net Change
medical medical-devices
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
by Indrajit Bandyopadhyay
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
IARTPositive Net Change FMSPositive Net Change STEPositive Net Change
medical medical-devices